Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Is there data to support the upfront use of encorafenib and cetuximab in metastatic BRAF V600E-mutated right-sided colon cancer?
Answer from: Medical Oncologist at Academic Institution
There is an ongoing trial (BREAKWATER) that will answer this but not yet.
Sign In
or
Register
to read more
22108
Related Questions
What patients with new onset diabetes require imaging of the pancreas?
With recent PFS data from LEAP-012 and Emerald-1, do you routinely offer for patients with intermediate BCLC stage HCC undergoing TACE or TARE systemic therapy (pembro/lenva or durve/bev)?
How would you treat newly diagnosed stage IV GEJ adenocarcinoma with both Claudin 18.2 and HER2 (3+ via IHC) overexpression?
How do you approach an isolated metastasis to left supraclavicular node in rectal cancer treated with TNT with FOLFOX regimen followed by long course radiation?
How do you plan to integrate exercise programs after adjuvant chemotherapy in patients with colon cancer, given the results of the CHALLENGE trial?
How does the presence of CNS disease affect your choice of first line therapy in Her2+ gastric adenocarcinoma?
Would you offer adjuvant therapy to a patient with a high grade mucinous appendiceal neoplasm that is pT3 pN0 M0, >12 lymph nodes removed with ileocecectomy?
How do you treat metastatic BRAF-mutated small bowel adenocarcinoma in the first-line setting?
In a patient with prior RT to the prostate and SVs and newly diagnosed, locally advanced rectal cancer at 10-15 cm, would you offer preoperative chemoradiation?
What are your top takeaways in GI Cancers from ASCO 2025?